Srikanth Deenadayalan

1.2k total citations · 2 hit papers
7 papers, 570 citations indexed

About

Srikanth Deenadayalan is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Srikanth Deenadayalan has authored 7 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 4 papers in Molecular Biology and 1 paper in Surgery. Recurrent topics in Srikanth Deenadayalan's work include Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (4 papers) and Diabetes Management and Research (3 papers). Srikanth Deenadayalan is often cited by papers focused on Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (4 papers) and Diabetes Management and Research (3 papers). Srikanth Deenadayalan collaborates with scholars based in Denmark, Japan and United States. Srikanth Deenadayalan's co-authors include Melanie J. Davies, Hirotaka Watada, Thalia Marie Blicher, Rafael Violante, Andreas L. Birkenfeld, Jacob Jacobsen, Julio Rosenstock, Pierre Sérusclat, Juan P. Frías and Sue D. Pedersen and has published in prestigious journals such as The Lancet, JAMA and Diabetes Care.

In The Last Decade

Srikanth Deenadayalan

7 papers receiving 555 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea

2019 302 citations Julio Rosenstock, Andreas L. Birkenfeld et al. JAMA profile →
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

2023 193 citations Juan P. Frías, Srikanth Deenadayalan et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Srikanth Deenadayalan Denmark	5	485	274	154	130	88	7	570
Tomoyuki Nishida Japan	14	672 1.4×	324 1.2×	187 1.2×	173 1.3×	86 1.0×	26	723
Stanislava Macura Denmark	7	350 0.7×	157 0.6×	142 0.9×	97 0.7×	96 1.1×	9	426
Juan José Gorgojo Martínez Spain	12	465 1.0×	167 0.6×	186 1.2×	166 1.3×	96 1.1×	30	586
J Lüdemann United States	6	589 1.2×	388 1.4×	177 1.1×	146 1.1×	76 0.9×	12	673
Masakazu Takeuchi Japan	13	479 1.0×	256 0.9×	130 0.8×	128 1.0×	72 0.8×	29	550
Bryan Goldman Denmark	7	415 0.9×	203 0.7×	208 1.4×	116 0.9×	73 0.8×	11	514
Edward Pratt United States	11	516 1.1×	164 0.6×	272 1.8×	144 1.1×	200 2.3×	24	703
Thalia Panagiotopoulou Greece	3	270 0.6×	100 0.4×	105 0.7×	92 0.7×	73 0.8×	3	373
J.P. Courrèges France	5	672 1.4×	338 1.2×	171 1.1×	308 2.4×	75 0.9×	7	734
Magnus F.G. Grøndahl Denmark	7	352 0.7×	169 0.6×	48 0.3×	207 1.6×	52 0.6×	13	419

Countries citing papers authored by Srikanth Deenadayalan

Since Specialization

Citations

This map shows the geographic impact of Srikanth Deenadayalan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srikanth Deenadayalan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srikanth Deenadayalan more than expected).

Fields of papers citing papers by Srikanth Deenadayalan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srikanth Deenadayalan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srikanth Deenadayalan. The network helps show where Srikanth Deenadayalan may publish in the future.

Co-authorship network of co-authors of Srikanth Deenadayalan

This figure shows the co-authorship network connecting the top 25 collaborators of Srikanth Deenadayalan. A scholar is included among the top collaborators of Srikanth Deenadayalan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srikanth Deenadayalan. Srikanth Deenadayalan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Frías, Juan P., Srikanth Deenadayalan, Lars Erichsen, et al.. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet. 402(10403). 720–730. 193 indexed citations breakdown →

2.

Yabe, Daisuke, Srikanth Deenadayalan, Hideaki Kaneto, et al.. (2022). Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials. Journal of Diabetes Investigation. 13(6). 975–985. 18 indexed citations

3.

Araki, Eiichi, Yasuo Terauchi, Hirotaka Watada, et al.. (2021). Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials. Diabetes Obesity and Metabolism. 23(12). 2785–2794. 9 indexed citations

4.

Bode, Bruce W., Violeta Iotova, М. А. Коваренко, et al.. (2019). Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. Diabetes Care. 42(7). 1255–1262. 46 indexed citations

5.

Rosenstock, Julio, Andreas L. Birkenfeld, Thalia Marie Blicher, et al.. (2019). SAT-139 Clinical Impact of Oral Semaglutide Compared with Sitagliptin in T2D on Metformin ± Sulfonylurea: The Pioneer 3 Trial. Journal of the Endocrine Society. 3(Supplement_1). 1 indexed citations

6.

Rosenstock, Julio, et al.. (2019). 111-LB: Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3. Diabetes. 68(Supplement_1). 1 indexed citations

7.

Rosenstock, Julio, Andreas L. Birkenfeld, Thalia Marie Blicher, et al.. (2019). Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea. JAMA. 321(15). 1466–1466. 302 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact